Biologics represent a new hope for big pharma and new dreams for biotech scientists.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
Orphanet Journal of Rare Diseases Open Access 09 June 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
08 May 2009
In the version of this article initially published, Joe Jimenez’s title was listed as CEO of Novartis. He is CEO of the Novartis Pharmaceuticals division. The error has been corrected in the HTML and PDF versions of the article.
Acknowledgements
I would like to thank the following for taking time to give valuable advice which will be of considerable benefit to the scientific community: Timothy Wells, Robert Lewis, Mervyn Turner, Lex Van der Ploeg, Johan Wallin, Jingsong Wang, Honghui Zhou, Reinhard Ebner, Sheldon Fan, Zhijian Lu, Paul Herrling, John Birch, Klaus Strein, Mike Shepard, Gianni Garotta, Jaume Pons, Peter Kiener, Seng Cheng, John Matthias, Morten Sogaard, Jean-Philippe Lopez, Jochen Salfeld, Thomas Li, Joe McCracken, Joerg Reinhardt, Joe Jimenez, Fu-Kuen Lin and John Maraganore. I also thank Yupeng He, Chi-Ming Lee, Jan Lundberg, Edmund Tsuei, Scott Wadsworth, Lee Babiss, Jonathan Knowles, Thomas Tan, Diane Pennica, Napoleone Ferrara, David Goeddel, Lou Tartaglia, Eric Kawashima, Steve Arkinstall, Richard Shamon, Chip Allee, Bill Cafruny, Heinz-Kurt Hochkeppel, Sidoney Atsé, Alex Pauling, Anto King and Jeff Browning for their excellent suggestions. The full responses from all the experts can be seen at http://www.studentvision.org and http://www.pauling.us
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wong, G. Biotech scientists bank on big pharma's biologics push. Nat Biotechnol 27, 293–295 (2009). https://doi.org/10.1038/nbt0309-293
Issue Date:
DOI: https://doi.org/10.1038/nbt0309-293
This article is cited by
-
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
Orphanet Journal of Rare Diseases (2021)
-
Extrinsic regulation of satellite cell specification
Stem Cell Research & Therapy (2010)
-
Erratum: Biotech scientists bank on big pharma's biologics push
Nature Biotechnology (2009)
